<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235885</url>
  </required_header>
  <id_info>
    <org_study_id>M04-724</org_study_id>
    <secondary_id>EudraCT: 2005/001185-14</secondary_id>
    <nct_id>NCT00235885</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)</brief_title>
  <acronym>STEREO</acronym>
  <official_title>Safety and Efficacy of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) - An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy, Including Patients Who Failed Prior Treatment With Other TNF-Inhibitors (STEREO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and clinical efficacy of adalimumab in
      active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard
      therapy including patients that have failed other TNF therapies
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety parameters</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>PsARC</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician Global Assessment for Psoriasis and Psoriasis Target Lesion Assessment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient reported outcomes</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>No differentiation will be made between primary and secondary efficacy variables.</measure>
  </secondary_outcome>
  <enrollment>445</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females &gt; 18 years of age

          -  Active PsA with &gt; 3 tender and &gt; 3 swollen joints despite standard therapy

          -  Unsatisfactory response or intolerance to at least one prior or ongoing DMARD (study
             enrollment must be in accordance with current national guidelines for treatment of PsA
             with TNF inhibitors)

          -  A negative serum pregnancy test (serum HCG) for women of childbearing potential prior
             to the start of treatment.

          -  Use of a reliable method of contraception by all female patients of childbearing
             potential

          -  Able and willing to self-administer sc injections or have a suitable person to
             administer sc injections

          -  Able and willing to give written informed consent and comply with the protocol

        Exclusion Criteria:

          -  Prior treatment with any investigational agent within 30 days or five half lives of
             the product, whichever is longer

          -  Treatment within last 2 months with infliximab or within last 3 weeks with etanercept

          -  Treatment within last 4 weeks with a combination of MTX and leflunomide

          -  Treatment within last 4 weeks with a combination of cyclosporine with any other
             DMARD-Subject has received UVA phototherapy (including PUVA within 2 weeks prior to
             screening)

          -  History of cancer or lymphoproliferative disease other than a successfully and
             completely treated squamous cell or basal cell carcinoma of the skin or cervical
             dysplasia

          -  History of or current active acute inflammatory joint disease of origin other than PsA

          -  Comorbidities (uncontrolled diabetes, unstable ischemic heart disease, CHF, active
             IBD, stroke within 3 months, chronic leg ulcer and other condition which would put
             subject at risk by participation in the protocol

          -  Positive serology for hepatitis B or C

          -  History of positive HIV status

          -  Persistent or recurrent infections or severe infections requiring hospitalization or
             treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior
             to enrollment

          -  Females who are pregnant or breast-feeding

          -  History of clinically significant drug or alcohol abuse in the last year

          -  Previous diagnosis or signs of central nervous system demyelinating diseases

          -  History of tuberculosis, histoplasmosis or listeriosis

          -  Subjects with latent TB or having other risk factors for activation of latent TB who
             have not initiated a TB prophylaxis prior to the first adalimumab treatment .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Paperiello</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Global Medical Information - Abbott</name>
      <address>
        <city>Abbott Park</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2005</study_first_submitted>
  <study_first_submitted_qc>October 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>August 28, 2007</last_update_submitted>
  <last_update_submitted_qc>August 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2007</last_update_posted>
  <keyword>Psoriatic Arthritis</keyword>
  <keyword>adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

